We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 51

Canada v. Pharmascience
  • Gowling WLG
  • Canada
  • July 27 2009

The Court of Appeal upheld the decision of the trial judge holding that the generic company was not required to address the patents listed on the patent register against submissions filed after it had purchased its comparator drug


Sanofi v. Hospira, merits of a 55.2 proceeding
  • Gowling WLG
  • Canada
  • December 3 2009

The Court refused to grant an Order of Prohibition against Hospira regarding its docetaxel product


Pfizer v. ratiopharm, motion to amended a previous judgment on the merits
  • Gowling WLG
  • Canada
  • December 3 2009

ratiopharm was successful in the proceeding under the NOC Regulations at the trial level, but the decision was overturned on appeal


Aventis v. Pharmascience; motion to set aside a previous order of prohibition; 2009 FC 915; ramipril; September 15, 2009
  • Gowling WLG
  • Canada
  • September 30 2009

Pharmascience had previously sent an Notice of Allegation (NOA) with respect to a patent to Aventis, resulting in a full hearing and appeal, concluding with an order of prohibition


Janssen-Ortho v. Apotex; motion for a stay; 2009 FCA 250; tramadol and acetaminophen; August 20, 2009
  • Gowling WLG
  • Canada
  • September 30 2009

In the Courts below, Apotex brought a motion to dismiss the application


Canada (Attorney General) v. Celgene Corporation, appeal of a PMPRB decision
  • Gowling WLG
  • Canada
  • January 20 2010

The Court of Appeal overturned the decision of the Trial Judge and restored the decision of the PMPRB providing jurisdiction to the PMPRB over medicines imported under the Special Access Program


Sanofi-Aventis v. ApotexNovopharmRiva, interlocutory motion to consolidate actions
  • Gowling WLG
  • Canada
  • January 20 2010

Sanofi brought a motion to consolidate three actions pertaining to damages pursuant to section 8 of the NOC Regulations


Pfizer v. Pharmascience, merits of NOC proceeding
  • Gowling WLG
  • Canada
  • January 20 2010

The Court granted prohibition to Pfizer and found that Pharmascience’s allegations of invalidity were not justified


Schering v. Pharmascience, merits of NOC proceeding
  • Gowling WLG
  • Canada
  • January 20 2010

The application under the NOC Regulations was dismissed


Apotex & Novopharm v. Wellcome; interlocutory motion to amend pleadings
  • Gowling WLG
  • Canada
  • November 2 2009

The Trial Division upheld the decision of the Prothonotary to allow GSK to amend its pleadings revising the quantum of damages sought in the proceeding